FIGURES 1A-D
002007-25T2960



FIGURE 1E


E
HIV-1 Expression (PIXELS)
1000
900
800
700
600
500
400
300
200
100
0
1
2
3
4
5
env
rev
nef

FIGURES 2A-D


Weight in Kg
p27 ng ml-1 of plasma
CD4+ T-cells mm-3
TIME (mos)
*UnRx *UnRx ♦Rx #Rx ⊕Rx
A
B
C
D

Figure 3 A & B

A

Log10 Viral Load (RT-PCR)

5
4
3
2
1
0

CD4+T Cells/ml

100
80
60
40
20
0

-6 -2 0.25 0.75 1 3 4 6 7

no additional therapy

3tc, d4t, Norvir, alpha-APA

B

IU hCG/Week*1,000

40
30
20
10
0

-6 -2 0.25 0.75 1 3 4 6 7

Duration hCG Treatment (Months)

Figures 3C and D





002001251/2960
*-Log10 Viral Load -▲-CD4 T cells/ml
PG8
E
Log10 Viral Load (Roche Amplicor)
6
5
4
3
2
1
0
-0.83
-0.23
0
0.47
0.93
1.87
2.8
no additional therapy
1000
800
400
200
0
F
IU hCG/week*1,000
40
30
20
10
0
-0.83
-0.23
0
0.47
0.93
1.87
Duration of hCG Treatment (mos)

Figures 3E&F

Figures 3G and H



Figures 3I and J



FIGURES 4A-D


A
B
C
D
p24 ng/ml
nmoles/ml
nmoles/ml
International units (IU/ml)
ahCG
b6-16
b109-119
b45-57
b45-57c
a88-92
APL
Sterls
pregnyl
CR127

FIGURES 5A-C

Effect of preparation of hCG on HIV-LTR activity



FIGURE 6A



8769-024



FIGURE 6-28


None
ahCG
hCGapl
NbhCG
CR127
b109-119
b45-57
b45-57c
bmix45+109
A
B
C
Number of colonies
1000
100
10
1
Cord
Marrow
CFU-Mix
BFU-e
CFU-GM

FIGURES 7A-C

FIGURE 8

```
AGACAAGGCA GGGGACGCAC CAAGG ATG GAG ATG TTC CAG GGG CTG CTG CTG                52
                            Met Glu Met Phe Gln Gly Leu Leu Leu
                            -20                 -15
TTG CTG CTG CTG AGC ATG GGC GGG ACA TGG GCA TCC AAG GAG CCG CTT
Leu Leu Leu Leu Ser Met Gly Gly Thr Trp Ala Ser Lys Glu Pro Leu               100
    -10                 -5                  1                   5
CGG CCA CGG TGC CGC CCC ATC AAT GCC ACC CTG GCT GTG GAG AAG GAG
Arg Pro Arg Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu               148
                10                  15                  20
GGC TGC CCC GTG TGC ATC ACC GTC AAC ACC ACC ATC TGT GCC GGC TAC
Gly Cys Pro Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr               196
            25                  30                  35
TGC CCC ACC ATG ACC CGC GTG CTG CAG GGG GTC CTG CCG GCC CTG CCT
Cys Pro Thr Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro               244
        40                  45                  50
CAG GTG GTG TGC AAC TAC CGC GAT GTG CGC TTC GAG TCC ATC CGG CTC
Gln Val Val Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu               292
    55                  60                  65
CCT GGC TGC CCG CGC GGC GTG AAC CCC GTG GTC TCC TAC GCC GTG GCT
Pro Gly Cys Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala               340
70                  75                  80                  85
CTC AGC TGT CAA TGT GCA CTC TGC CGC CGC AGC ACC ACT GAC TGC GGG
Leu Ser Cys Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly               388
                90                  95                  100
GGT CCC AAG GAC CAC CCC TTG ACC TGT GAT GAC CCC CGC TTC CAG GAC
Gly Pro Lys Asp His Pro Leu Thr Cys Asp Asp Pro Arg Phe Gln Asp               436
            105                 110                 115
TCC TCT TCC TCA AAG GCC CCT CCC CCC AGC CTT CCA AGC CCA TCC CGA
Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg               484
        120                 125                 130
CTC CCG GGG CCC TCG GAC ACC CCG ATC CTC CCA CAA TAAAGGCTTC
Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln                               530
    135                 140                 145
TCAATCCGC                                                                    539
```

FIGURES 9A&B

A.



B.



Figures 10A-F



Figure11



Figure 13


Tumor sizes (% of Inhibition)
100
80
60
40
20
0
PBS
APL
---HAF-UF#-------
---HAF-CF#----------
Treatment
76
65
26
62
65
82
74
76
35

Figures 12A-C



Figure 14



Figure 15A

Viral Load Change after HAF



Figure 15B

CD4 Change After HAF



Figure 15C

Viral Load Versus HAF Dose



HCGIU

Figures 16A and B



174

FIGURE



Method: PRO60K_L
Mode: Linear

Accelerating Voltage: 25000
Grid Voltage: 88.000 %
Guide Wire Voltage: 0.200 %
Delay: 300 ON

Laser : 2600
Scans Averaged: 52
Pressure: 4.64e-07
Low Mass Gate: 500.0

Collected: 1/28/97 8:06 PM
Mirror Ratio: 1.060
PSD Mirror Ratio:
Timed Ion Selector: 15.5 OFF
Negative Ions: OFF

FIGURE 17B



Collected: 1/28/97 8:11 PM

Method: PRO60K_L
Mode: Linear

Accelerating Voltage: 25000
Grid Voltage: 88.000 %
Guide Wire Voltage: 0.200 %
Delay: 300 ON

Laser : 2700
Scans Averaged: 90
Pressure: 3.40e-07
Low Mass Gate: 500.0

Mirror Ratio: 1.060
PSD Mirror Ratio:
Timed Ion Selector: 15.5 OFF
Negative Ions: OFF

FIGURE 17C



Method: PRO60K_L
Mode: Linear

Accelerating Voltage: 25000
Grid Voltage: 88.000 %
Guide Wire Voltage: 0.200 %
Delay: 300 ON

Laser : 2408
Scans Averaged: 125
Pressure: 3.12e-07
Low Mass Gate: 500.0

Mirror Ratio: 1.060
PSD Mirror Ratio:
Timed Ion Selector: 15.5 OFF
Negative Ions: OFF

FIGURE 17D



Method: PRO60K_L
Mode: Linear

Accelerating Voltage: 25000
Grid Voltage: 88.000 %
Guide Wire Voltage: 0.200 %
Delay: 300 ON

Laser : 2700
Scans Averaged: 57
Pressure: 3.02e-07
Low Mass Gate: 500.0

Collected: 1/28/97 8:14 PM
Mirror Ratio: 1.060
PSD Mirror Ratio:
Timed Ion Selector: 15.5 OFF
Negative Ions: OFF

0967152 .100200

FIGURE 17E



Method: PRO60K_L
Mode: Linear

Accelerating Voltage: 25000
Grid Voltage: 88.000 %
Guide Wire Voltage: 0.200 %
Delay: 300 ON

Laser : 2700
Scans Averaged: 45
Pressure: 2.87e-07
Low Mass Gate: 500.0

Mirror Ratio: 1.060
PSD Mirror Ratio:
Timed Ion Selector: 15.5 OFF
Negative Ions: OFF



FIGURES 18 A-H

FIGURE 19


Series2
Series1
Inhibition in %
60.00
50.00
40.00
30.00
20.00
10.00
-
Prostate (colonogenic assay)
no. of colonies
90
80
70
60
50
40
30
20
10
0
pbs
api100
apl200
60
61
62
63
64
65
71
72
73
74
75
alpha
apl-d
treatments

Systemic Effects of hCG Preparation or ChCG Peptide Induces Apoptosis in Prostate Tumors of Nude Mice



FIGURES 20A-C



FIGURE 21


Clonogenic Assay lung 177
No. of colonies
% Inhibition
Treatment
Colonies
Inhibition%
100ul PBS
APL100
APL200
SalA2100
SalA2200
uf60/200
uf84/200
uf74/200
apl60/200
apl64/200
apl74/200

FIGURE 22A


Clonogenic Assay Lung 177/p46
No. of Colonies
% Inhibition
Colonies
Inhibition%
Treatment
100ulTPBS
APL100
SalA1100
SalA2100
SalAB100

FIGURE 22B


Clonogenic Assay Lung 177/p52
No. of Colonies
90
80
70
60
50
40
30
20
10
0
% Inhibition
70%
60%
50%
40%
30%
20%
10%
0%
100ulPBS
APL100
APL200
SalA2100
SalA2200
ul60/200
ul84/200
ul74/200
apl160/200
apl184/200
apl174/200
Treatment
Colonies
Inhibition%

FIGURE 22C

Lung Cancer

A	B	C
Lung 177/Neg		
D	E	F



FIGURES 23A-F

FIGURES 24 A-I